Jacobson Pharma (HKSE:02633) ROCE % : 12.63% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Jacobson Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jacobson Pharma's annualized ROCE % for the quarter that ended in Sep. 2024 was 12.63%.

Jacobson Pharma ROCE % Historical Data

The historical data trend for Jacobson Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobson Pharma ROCE % Chart

Jacobson Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

9.03

6.39

6.49

7.21

8.50

Jacobson Pharma Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
ROCE %	Get a 7-Day Free Trial															7.55	6.36	8.75	11.14	12.63

Jacobson Pharma ROCE % Calculation

Jacobson Pharma's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	333.291	/	( ( (5380.499 - 656.435)	+	(3486.854 - 372.843) )	/ 2 )
	=	333.291	/	( (4724.064	+	3114.011)	/ 2 )
	=	333.291	/	3919.0375
	=	8.50 %

Jacobson Pharma's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	391.81	/	( ( (3486.854 - 372.843)	+	(3606.697 - 516.489) )	/ 2 )
	=	391.81	/	( ( 3114.011	+	3090.208 )	/ 2 )
	=	391.81	/	3102.1095
	=	12.63 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

Jacobson Pharma (HKSE:02633) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jacobson Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Jacobson Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jacobson Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jacobson Pharma Corp Ltd (HKSE:02633) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

388 Kwun Tong Road, Unit 2313-18, 23rd Floor, Tower 1, Millennium City 1, Kwun Tong, Kowloon, Hong Kong, HKG

Website

http://www.jacobsonpharma.com

Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.

Executives

Sum Kwong Yip, Derek	2305 Beneficiary of a trust
Lau Wing Hung
Kingshill Development Group Inc
Kingshill Development Limited
Ubs Trustees (b.v.i.) Limited
Queenshill Development Limited
Longjin Investments Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si

Jacobson Pharma Headlines

No Headlines